Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Open accessThe DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful. The relative toxicity of TCAs continues to be more precisely defined, as do TCA interactions with selective serotonin reuptake inhibitors (SSRIs). TCA interactions with monoamine oxidase inhibitors (MAOIs) have been, historically, an uncertain and difficult question, but are now well understood, although this is not reflected in the literature. The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs. Clomipramine is the only available antidepressant drug that has good evidence of clinically relevant serotonin and noradrenaline reuptake inhibition (SNRI). These data assist drug selection for monotherapy and combination therapy and predict reliably how and why pharmacodynamic and pharmacokinetic interactions occur. In comparison, two newer drugs proposed to have SNRI properties, duloxetine and venlafaxine, may have insufficient NRI potency to be effective SNRIs. Combinations such as sertraline and nortriptyline may therefore offer advantages over drugs like venlafaxine that have fixed ratios of SRI/NRI effects that are not ideal. However, no TCA/SSRI combination is sufficiently safe to be universally applicable without expert knowledge. Standard texts (e.g. the British National Formulary) and treatment guidelines would benefit by taking account of these new data and understandings. British Journal of Pharmacology (2007) 151 , 737–748; doi: 10.1038/sj.bjp.0707253
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, different TCAs inhibit 5-HT and NE reuptake to varying degrees.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [344]
In the citing paper
“For instance, amitriptyline, imipramine, and desipramine strongly inhibit 5-HT reuptake, 344”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [344]
Citations
Cites
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816 · cited 1×
“That result accords with a review covering 37 studies about sponsorship that showed a significant association between industry sponsorship and pro-industry conclusions (Bekelman et al., 2003).”
ResultIngelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 635
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 538
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 3×
“The PET study of SERT binding from Meyer et al. (2004) demonstrates comparable SERT antagonism in human striatum (B80”
BackgroundInfluential
Research works printed but not linked: 6
- 10.1002/(SICI)1520-6394(1997)5:2<84::AID-DA4>3.0.CO;2-5 · DOI
- 10.1002/(SICI)1520-6394(1998)7:1 <11::AID-DA4>3.0.CO;2-I · doi:10.1002/(sici)1520-6394(1998)7:1
- Brunton LL, 2006, Goodman and Gilman's The Pharmacologicl Basis of Therapeutics
- Dawson AH, 2004, Med Toxicol, 851
- Preskorn S, 2006, 2006 guide to psychiatric drug interactions, Primary Psychiatry, 13, 35
- Whyte IM, 2004, Med Toxicol, 843
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“…SNRIs can all inhibit the reuptake of 5-HT by SERTs, specially SSRIs have the selective inhibition on SERTs, which increase the concentration of 5-HT in the synaptic gap and play antidepressive roles by effecting on 5-HTRs in postsynaptic membrane, 343,344 which also activate the cAMP-PKA pathway.”
BackgroundAGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“, 2014); TCA (Anderson, 2000; Cohn et al., 1996; Danish University Antidepressant Group, 1986; Danish University Antidepressant Group, 1990; Danish University Antidepressant Group, 1993; Doogan and Langdon, 1994; Fabre et al., 1996; Feighner and Boyer, 1989; Furukawa et al., 2009; Gillman, 2007; Guaiana et al., 2007;…”
BackgroundSLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Exercise as a treatment for depression: A meta-analysis
Kvam, S., Kleppe, C. L., Nordhus, I. H., & Hovland, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.03.063 · Cited by 837
Hicks, J., Sangkuhl, K., Swen, J., Ellingrod, V., Müller, D., Shimoda, K., Bishop, Jr., Kharasch, E., Skaar, T., Gaedigk, A., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.597 · Cited by 685
Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 453
Uher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010094 · Cited by 418
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“In general, newer antidepressants are better tolerated than the tricyclic antidepressants and monoamine oxidases owing in part to the reduced side effect burden (Gillman, 2007).”
BackgroundThe solute carrier 6 family of transporters
Bröer, S., & Gether, U. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01975.x · Cited by 269
Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
Scotton, W. J., Hill, L. J., Williams, A. C., & Barnes, N. M. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919873925 · Cited by 267
Tranylcypromine in mind (Part I): Review of pharmacology
Ulrich, S., Ricken, R., & Adli, M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.05.007 · Cited by 237
Nguyen, H. G., Yang, J. C., Kung, H.-J., Shi, X.-B., Tilki, D., Lara, P. N., DeVere White, R. W., Gao, A. C., & Evans, C. P. (2014) · Oncogene · doi:10.1038/onc.2014.25 · Cited by 212
Nonnarcotic Methods of Pain Management
Finnerup, N. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807061 · Cited by 153
Venkatesan, T., Levinthal, D. J., Tarbell, S. E., Jaradeh, S. S., Hasler, W. L., Issenman, R. M., Adams, K. A., Sarosiek, I., Stave, C. D., Sharaf, R. N., et al. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13604 · Cited by 137
Feather damaging behaviour in parrots: A review with consideration of comparative aspects
van Zeeland, Y. R. A., Spruit, B. M., Rodenburg, T. B., Riedstra, B., van Hierden, Y. M., Buitenhuis, B., Korte, S. M., & Lumeij, J. T. (2009) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2009.09.006 · Cited by 139
A Social Media Study on the Effects of Psychiatric Medication Use
Saha, K., Sugar, B., Torous, J., Abrahao, B., Kıcıman, E., & De Choudhury, M. (2019) · Proceedings of the International AAAI Conference on Web and Social Media · doi:10.1609/icwsm.v13i01.3242 · Cited by 96
“Antidepressant research has grown tremendously, ever since Imipramine, and other Tricyclic Antidepressants (TCAs) were discovered and found to be effective (Gillman 2007).”
BackgroundSchizo-obsessive spectrum disorders: an update
Scotti-Muzzi, E., & Saide, O. L. (2017) · CNS Spectrums · doi:10.1017/s1092852916000390 · Cited by 65
Practical guide for prescribing MAOIs: debunking myths and removing barriers
Grady, M. M., & Stahl, S. M. (2012) · CNS Spectrums · doi:10.1017/s109285291200003x · Cited by 51
Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation
Caldara, M., & Marmiroli, N. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.06.023 · Cited by 31
Metadata
- Authors
- Gillman, P. K.
- Affiliations
- PsychoTropical Research (AU)
- Corresponding author
- Gillman, P K
- ORCID
- Gillman, P K
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-07
- Volume
- 151
- Issue
- 6
- Pages
- 737-748
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2014120
- OpenAlex
- W2155964805
- Cited by
- 694
- References
- 132
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 51 · 2023: 43 · 2022: 60 · 2021: 52 · 2020: 43 · 2019: 36 · 2018: 39 · 2017: 42 · 2016: 35 · 2015: 27 · 2014: 30 · 2013: 31 · 2012: 37
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- tricyclic antidepressants, drug interactions, cytochrome P450 inhibition, nortriptyline, desipramine, clomipramine, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, norepinephrine reuptake inhibition, duloxetine, venlafaxine, sertraline, combination therapy
- MeSH terms
- Animals, Antidepressive Agents, Tricyclic, Central Nervous System, Cytochrome P-450 Enzyme System, Drug Interactions, Drug Therapy, Combination, Humans, Monoamine Oxidase Inhibitors, Selective Serotonin Reuptake Inhibitors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.